• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMERIEUX INC. VITEK®2 AST-GP71 TEST KIT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMERIEUX INC. VITEK®2 AST-GP71 TEST KIT Back to Search Results
Model Number 410750
Medical Device Problem Code Incorrect, Inadequate or Imprecise Result or Readings (1535)
Health Effect - Clinical Code No Consequences Or Impact To Patient (2199)
Type of Reportable Event Malfunction
Event or Problem Description
A customer in the united states notified biomérieux of discrepant results involving s.Aureus associated with vitek®2 ast-gp71 test kit.The customer reported they had seventeen (17) cards with resistant oxacillin and repeat testing on vitek® 2 reported the result as susceptible.There is no indication or report from the laboratory or physician that the discrepant result led to any adverse event related to a patient's state of health.An internal biomérieux investigation will be initiated.
 
Additional Manufacturer Narrative
A customer in the united states notified biomérieux of discrepant oxacillin results associated with vitek®2 ast-gp71 test kit.A biomérieux investigation was performed.The investigation was initiated in response to customer complaints reporting holes in the white card pouches of some cards at the stitch seam.The root cause of the defect was linked to the design of the wheel that applies the stitch seal to the pouch.On (b)(6)2017, the stitch wheels with a new design were installed that resolved the issue.There are no documented studies to indicate which substrates are moisture sensitive in the vitek® 2 id cards and what type of atypical reactions these may cause.However, the id algorithm generally allows two (2) atypical reactions and will still give an identification with a high degree of confidence.The knowledge bases are designed to account for both typical and atypical strains so an aberrant reaction should have low impact on identification results.For gn & gp, a kinetic algorithm is used, which means that identifications are attempted every 15 minutes starting at 2 hours.A kinetic algorithm does not necessarily use all the tests on the card to make an identification, which also reduces the impact of an atypical result for these two cards.Urea has shown some sensitivity to moisture by giving a false positive reaction.Therefore, data analysis was performed where the urea well (ure) results stored in the knowledge base for all test isolates were forced to be initial value positive to evaluate a worst case scenario.Five (5) out of the seven (7) id cards (anc, gn, gp, nh and yst) were evaluated.Cbc was not manufactured in the white webbing during 12sep2016 and 17mar2017 and bcl does not contain ure.The results show that all but one (1) card gave 95% identification agreement between the knowledge bases in vitek® 2 7.01 software and the knowledge bases, which were altered to give all ure positive results.The id card that did not meet the 95% agreement rate was anc at 92.8% with ci (92.2%, 93.5%).Based on this analysis, gn, gp, yst and nh show no significant impact on performance when ure is forced positive.Anc did not meet the criteria but is within 2.2% of meeting it.The antimicrobials most affected by moisture include the beta-lactams, primarily carbapenems and penicillins, and some cephalosporins, but not all cephalosporins are affected the same.Beta-lactams are more sensitive in general to moisture, due to their structure.The main degradation is hydrolysis, which means a molecule of beta-lactam reacts with a molecule of water.Other main antimicrobial classes, such as fluoroquinolones, or aminoglycosides, are not considered moisture sensitive.Macrolides generally are not moisture sensitive, but erythromycin is.Also affected by moisture is nitrofurantoin (furanes class), and clavulanic acid (a beta-lactamase inhibitor, used in combination with a penicillin, or in combination with cephalosporins, as in the case of the esbl test).The moisture will tend to degrade the antimicrobial, so the effect is less antimicrobial available in the vitek® 2 well, and therefore, the expected effect on results would be elevated mics, or false resistance.One exception would be the esbl test, which could be falsely negative, if the clavulanic acid was degraded due to moisture.For ast-gn cards, at least one carbapenem would be included in the card configuration, and the card would likely include a penicillin, and multiple cephalosporins.For ast-gp cards, the card configuration would usually include at least one penicillin, usually oxacillin, and usually nitrofurantoin.The expected result of tears/holes in the pouch due to the previous stitch seal would be moisture degradation of the antimicrobials, thereby elevating the mics, or causing false resistance.If mics were elevated enough to change the interpretation of the result from s to i, or i to r, or s to r, then the risk is that an antimicrobial that may have been a first line therapy may not be used.If this occurred for multiple antimicrobials, several that may have been candidates for therapy may be excluded.The exception to the false resistance or elevated mics would be the esbl test, which could be falsely negative.This test is primarily used for epidemiology purposes, or infection control, and not necessarily for treatment.Field safety corrective action (fsca) 3445 was issued on 19apr2017 to impacted biomérieux subsidiaries and distributors to notify customers of this issue.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VITEK®2 AST-GP71 TEST KIT
Common Device Name
VITEK®2 AST-GP71 TEST KIT
Manufacturer (Section D)
BIOMERIEUX INC.
595 anglum road
saint louis MO 63042
MDR Report Key6653437
Report Number1950204-2017-00194
Device Sequence Number11050179
Product Code LON
UDI-Device Identifier03573026355173
UDI-Public03573026355173
Combination Product (Y/N)N
Initial Reporter StateHI
Initial Reporter CountryUS
PMA/510(K) Number
N50510: S117
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional,user faci
Initial Reporter Occupation Health Professional
Type of Report Initial,Followup
Report Date (Section B) 09/15/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date07/12/2018
Device Model Number410750
Device Lot Number2710228103
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer 04/19/2017
Supplement Date Received by Manufacturer06/23/2017
Initial Report FDA Received Date06/20/2017
Supplement Report FDA Received Date09/15/2017
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
If action reported to FDA under 21 USC 360i(g), list
FDA-assigned Recall Number or include a statement
FSCA 3445
Patient Sequence Number1
-
-